It’s generally taken for granted that insulin resistance and Type 2 diabetes are best addressed through diet and exercise. Medications, including…
Category: Other Treatments
When our daughter, Bisi, was first diagnosed with type 1 diabetes, we received three days of intensive training in the hospital before we were allowed…
Who’s got your back? Who have you trained on your emergency Glucagon kit? When you – or the person with Type 1 diabetes in your life – has a severe hypo,…
The U.S. Food and Drug Administration (FDA) has approved Lilly’s BAQSIMI (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia…
While insulin and insulin pumps have evolved into highly technical and effective tools for treating diabetes, the method for delivering emergency…
A 12-year old South Carolina girl with Type 1 diabetes and what her parents describe as an intense allergy to insulin therapy is set to undergo a rarely…
Rather than telling patients they’re wrong, I try to give them the tools to make good decisions about their health. Guilt is not a motivator. And we tend to overlook baby steps. It’s not realistic to tell a patient to change their entire diet overnight. But asking a patient to cut out one thing, sodas, for example, can make a big impact on overall health.
Another insulin coming to us in 2016 is Lilly’s new basal insulin, Basaglar – a form of insulin glargine (which you may recognize if you’re familiar with Lantus). FDA approved it just this week after a patent dispute was finally resolved with Sanofi.
JDRF announced that JDRF-funded partner, ViaCyte, Inc. has for the first time ever implanted a person with type 1 diabetes with an experimental encapsulated cell therapy product candidate, called VC-01, which is being developed for the treatment of type 1 diabetes. This individual, and others to follow, is participating in a trial to evaluate the safety and efficacy of the VC-01 product candidate, a potential replacement source of insulin-producing cells.
In anticipation of stable, liquid glucagon, one of the newest entrants into the insulin pump space, Tandem Diabetes Care has jumped ahead of the crowd and created a two-chamber infusion pump capable of holding and injecting both insulin and a secondary hormone, which they expect will be glucagon. This tandem Tandem pump is already being tested in Dr. Ed Damiano's clinical trial of a dual-hormone bionic pancreas.